Subtype-Specific Divergent Roles of Calpain-1 and Calpain-2 in Basal a Triple-Negative Breast Cancer
| dc.contributor.author | Uner, Goklem | |
| dc.contributor.author | Oztarhan, Gokhan | |
| dc.contributor.author | Kirmizibayrak, Petek Ballar | |
| dc.date.accessioned | 2025-11-25T15:10:10Z | |
| dc.date.available | 2025-11-25T15:10:10Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | BackgroundCAPN-1 and CAPN-2, two ubiquitously expressed calpains, have been implicated in cancer progression, but their distinct roles in breast cancer remain poorly defined. This study aims to define the opposing roles of CAPN-1 and CAPN-2 in breast cancer progression, with a focus on their regulatory impact on cell proliferation. Since these calpains may have different functions in the mammary gland, we aimed to investigate the possible antagonistic roles of CAPN-1 and CAPN-2 in breast cancer progression, focusing on their expression patterns and functional impact on cell proliferation.Methods and resultsWe analyzed breast cancer cell lines using immunoblotting and real-time cellular assays, showing that HCC1937 cells exhibit an opposite expression pattern of CAPN-1 and CAPN-2 compared to non-cancerous breast cells. CAPN-1 promoted cancer cell survival and negatively regulated CAPN-2 at both the protein and mRNA levels, whereas CAPN-2 suppressed proliferation. Additionally, the calpain activator AG-08 triggered cell death through CAPN-2 but not CAPN-1. In silico analysis confirmed higher CAPN-1 and lower CAPN-2 expression levels in breast cancer samples compared to normal tissue.ConclusionsThese findings indicate that CAPN-1 and CAPN-2 may exert antagonistic roles in breast cancer, but importantly, this effect was restricted to HCC1937 cells, representing a basal A TNBC subtype. Validation in additional basal A models and patient-derived samples will be essential to confirm these results. Our study, therefore, provides preliminary, model-specific insights into calpain regulation in TNBC and suggests that future therapeutic strategies should carefully account for subtype heterogeneity. | en_US |
| dc.description.sponsorship | Ege University, Office of Scientific Research Projects; Pharmaceutical Sciences Research Centre (FABAL, Ege University, Faculty of Pharmacy) | en_US |
| dc.description.sponsorship | We thank the Pharmaceutical Sciences Research Centre (FABAL, Ege University, Faculty of Pharmacy) for equipment support. | en_US |
| dc.identifier.doi | 10.1186/s12860-025-00556-6 | |
| dc.identifier.issn | 2661-8850 | |
| dc.identifier.scopus | 2-s2.0-105019034768 | |
| dc.identifier.uri | https://doi.org/10.1186/s12860-025-00556-6 | |
| dc.identifier.uri | https://hdl.handle.net/11147/18643 | |
| dc.language.iso | en | en_US |
| dc.publisher | BMC | en_US |
| dc.relation.ispartof | BMC Molecular and Cell Biology | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Breast Cancer | en_US |
| dc.subject | Calpain-1 | en_US |
| dc.subject | Calpain-2 | en_US |
| dc.subject | Proteases | en_US |
| dc.subject | Cancer Treatment | en_US |
| dc.title | Subtype-Specific Divergent Roles of Calpain-1 and Calpain-2 in Basal a Triple-Negative Breast Cancer | |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.scopusid | 57219944322 | |
| gdc.author.scopusid | 7003998497 | |
| gdc.author.scopusid | 57222366085 | |
| gdc.author.wosid | Bedir, Erdal/Abi-3895-2020 | |
| gdc.author.wosid | Ballar Kirmizibayrak, Petek/Y-6869-2018 | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Institute of Technology | en_US |
| gdc.description.departmenttemp | [Uner, Goklem; Bedir, Erdal] Izmir Inst Technol, Fac Engn, Dept Bioengn, TR-35430 Izmir, Turkiye; [Kirmizibayrak, Petek Ballar] Ege Univ, Fac Pharm, Dept Biochem, TR-35100 Izmir, Turkiye | en_US |
| gdc.description.issue | 1 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q3 | |
| gdc.description.volume | 26 | en_US |
| gdc.description.woscitationindex | Science Citation Index Expanded | |
| gdc.description.wosquality | Q3 | |
| gdc.identifier.openalex | W4415267523 | |
| gdc.identifier.pmid | 41102637 | |
| gdc.identifier.wos | WOS:001595360200001 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 0.0 | |
| gdc.openalex.normalizedpercentile | 0.41 | |
| gdc.opencitations.count | 0 | |
| gdc.plumx.scopuscites | 0 | |
| gdc.scopus.citedcount | 0 | |
| gdc.wos.citedcount | 0 | |
| relation.isAuthorOfPublication.latestForDiscovery | 461a570d-2493-4349-b634-a876ced8cd22 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 9af2b05f-28ac-4003-8abe-a4dfe192da5e |
